135 related articles for article (PubMed ID: 22820139)
1. Clinical significance of suppressor of cytokines signalling-3 mRNA expression from patients with non-Hodgkin lymphoma under chemotherapy.
Attia FM; Hassan AM; El-Maraghy NN; Ibrahium GH
Cancer Biomark; 2011-2012; 11(1):41-7. PubMed ID: 22820139
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease.
Rastmanesh MM; Bluyssen HA; Joles JA; Boer P; Willekes N; Braam B
Eur J Pharmacol; 2008 Sep; 593(1-3):99-104. PubMed ID: 18656467
[TBL] [Abstract][Full Text] [Related]
3. Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality.
Rastmanesh MM; Braam B; Joles JA; Boer P; Bluyssen HA
Eur J Pharmacol; 2009 Jan; 602(1):163-7. PubMed ID: 19041303
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.
Uskudar Teke H; Gulbas Z; Bal C
J BUON; 2014; 19(1):191-7. PubMed ID: 24659663
[TBL] [Abstract][Full Text] [Related]
5. Expression of suppressor of cytokine signaling 1 in the peripheral blood of patients with idiopathic pulmonary fibrosis.
Bao Z; Zhang Q; Wan H; He P; Zhou X; Zhou M
Chin Med J (Engl); 2014; 127(11):2117-20. PubMed ID: 24890164
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of some inflammatory markers in patients with lymphoma.
Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
[No Abstract] [Full Text] [Related]
7. The expression of SOCS is altered in rheumatoid arthritis.
Isomäki P; Alanärä T; Isohanni P; Lagerstedt A; Korpela M; Moilanen T; Visakorpi T; Silvennoinen O
Rheumatology (Oxford); 2007 Oct; 46(10):1538-46. PubMed ID: 17726036
[TBL] [Abstract][Full Text] [Related]
8. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
9. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
10. The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors.
Shen X; Wang M; Guo Y; Ju S
Adv Clin Exp Med; 2016; 25(5):837-844. PubMed ID: 28028945
[TBL] [Abstract][Full Text] [Related]
11. Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines.
Santangelo C; Scipioni A; Marselli L; Marchetti P; Dotta F
Eur J Endocrinol; 2005 Mar; 152(3):485-9. PubMed ID: 15757867
[TBL] [Abstract][Full Text] [Related]
12. [Association between suppressors of cytokine signaling mRNA expression and Th1/Th2 balance in children with asthma].
Hui Y; Xie JJ; Li L; Xiang HX; Mu HJ; Yin Y; Zhang XJ
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):755-8. PubMed ID: 23092567
[TBL] [Abstract][Full Text] [Related]
13. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
14. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood.
Han MH; Eom HS; Park WS; Yun T; Park S; Kim HJ; Jeon CH; Kong SY
Leuk Res; 2010 Sep; 34(9):1127-31. PubMed ID: 20036422
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
17. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between the expression of murine double minute 2 oncogene and non-Hodgkin lymphoma in childhood].
Liu Z; Long GF; Han YL; Wei HY
Zhonghua Er Ke Za Zhi; 2004 Dec; 42(12):928-31. PubMed ID: 15733365
[TBL] [Abstract][Full Text] [Related]
19. [Expression of suppressor of cytokine signaling in peripheral blood monocular cells of patients with Vogt-Koyanagi-Harada disease].
Liu YX; Wang H; Peng XY; Zhou ZC
Zhonghua Yan Ke Za Zhi; 2009 Nov; 45(11):1015-9. PubMed ID: 20137421
[TBL] [Abstract][Full Text] [Related]
20. [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].
Zhang DS; Jiang WQ; Li S; Zhang XS; Mao H; Chen XQ; Li YH; Zhan J; Wang FH
Ai Zheng; 2003 Aug; 22(8):870-3. PubMed ID: 12917038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
